Magnetic tracer in the sentinel node procedure in breast cancer: the non-radioactive alternative for radio-isotopes

Magnetic tracer in the sentinel node procedure in breast cancer: the non-radioactive alternative for radio-isotopes - MagTrace

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON49099

Enrollment

Registered

2021-02-01

Start date

2021-07-20

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sentinel node procedure

Interventions

Intervention group This is a prospective cohort of all patients with breast cancer and an indication for a sentinel node procedure. These patients will be injected with the magnetic tracer (Magtrac

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Female patient of 18 years or older. - Patient with breast cancer and indication for sentinel node procedure.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Patients with a previous history of the sentinel node procedure or axillary lymph node dissection in the ipsilateral breast. - Hypersensitivity for ironoxide or dextran

Design outcomes

Primary

Measure	Time frame
To assess 1. The concordance in detection of sentinel nodes by Magtrace and the Technetium tracer.	—

Secondary

Measure	Time frame
1. Operation time sentinel node procedure	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)